Ημερομηνία: 5/9/2007 7:03:00 πμ Περιοχή: Νέα Υόρκη ΗΠΑ Από: BW

Μεγέθυνση - Σμίκρυνση

( BW)(WA-HELIX-BIOMEDX/DEGUSSA)(HXBM) Degussa Goldschmidt Personal Care and Helix BioMedix announce Partnership on Peptides Business Editors/Health/Medical Writers BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 5, 2007--Goldschmidt GmbH, a wholly owned subsidiary of Degussa GmbH and leading global manufacturer of raw materials, additives and active ingredients for the cosmetic industry, and Helix BioMedix, Inc., (OTCBB: HXBM), a biopharmaceutical company with an extensive library of diverse bioactive peptides, today announced an agreement through which Degussa Goldschmidt Personal Care will become Helix BioMedix's exclusive marketing partner for its Combikine(TM) and Replikine(TM) class of anti-aging peptides in addition to other selected peptides targeted at skin care applications. "We are extremely pleased about our agreement with Helix BioMedix since it will allow us to complement our existing product portfolio of specialty and active ingredients for the cosmetic industry," remarks Willy Klipp, Senior Vice President and General Manager of Goldschmidt, Personal Care. "This cooperation is a further important move in growing our customer relationships and guaranteeing the consistent implementation of our overall strategy. We are currently evaluating several peptides and plan that initial products developed as a result of this partnership will be commercially available as of 2008." "Partnering with a company of Degussa's stature will assist us as we continue to commercialize our innovative peptides," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix. "Degussa Goldschmidt Personal Care is one of the leading manufacturers of cosmetic ingredients worldwide, with an impressive portfolio and an excellent reputation for product development and service. We look forward to continuing our work with them, and anticipate that over the term of this agreement our joint efforts will produce many innovative personal care products covering a variety of applications and benefits." "Bioactive peptides are emerging as some of today's most promising answers to the constant demand for innovation in bio-science," explains Dr. Mike Farwick, Head of R&D Active Ingredients for Goldschmidt, Personal Care. "Accessing Helix BioMedix's portfolio of innovative peptides and combining it with our extensive formulation know-how and claims validation capabilities substantially supports our competitive advantage in creating the next generation of safe and effective personal care products." About Goldschmidt GmbH Goldschmidt GmbH's business line Personal Care is a leading global manufacturer and supplier of raw materials, additives, and active ingredients for the cosmetics industry. All business activities are strongly supported by application technology, as well as by own in-house research & development. A dedicated team of highly skilled professionals is committed to excellence and customer satisfaction. Among other products Goldschmidt is specialised in manufacturing human skin identical sphingolipids including Ceramides by biotech means. Screening, identification and confirmation of biological activities for novel ingredients is carried with state-of-the-art cell and molecular biology including the use of DNA-Chip technology, cell cultures, artificial skin models and the validation of results in in-vivo studies. About Helix BioMedix, Inc. Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. The company's mission is to enrich clinical practice and the patient/consumer experience by developing topically applied products that offer the health, beauty and safety benefits of advanced bioactive small molecule technology. The Company's vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology. The core competencies of Helix BioMedix include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company has the capability to take product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, the company is developing finished, peptide-based products to market with its partners. More information about Helix BioMedix and its proprietary peptides may be found on the company's website at www.helixbiomedix.com. Forward-Looking Statements This press release contains forward-looking statements regarding Helix BioMedix, Inc. (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the Helix BioMedix, Inc. website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. Helix BioMedix, Inc. undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances. CONTACT: Degussa GmbH Betty Santonnat Marketing Manager, Actives Phone/Fax 334 75 4180 99 betty.santonnat@degussa.com or Helix BioMedix R. Stephen Beatty, 425-402-8400 President and CEO sbeatty@helixbiomedix.com or Investors: Shelton Group Investor Relations Ryan Bright, 972-239-5119 X 159 rbright@sheltongroup.com KEYWORD: WASHINGTON GERMANY FRANCE INTERNATIONAL EUROPE INDUSTRY KEYWORD: BIOTECHNOLOGY CONSUMER/HOUSEHOLD RETAIL MARKETING AGREEMENTS SOURCE: Helix BioMedix, Inc. and Degussa GmbH Copyright Business Wire 2007